Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -30.00%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.14, delivering a surprise of +7.69%.Over the last four quarters, the company ha ...

Certara (CERT) Q2 2025 Earnings Call August 06, 2025 05:00 PM ET Speaker0Good day, and thank you for standing by. Welcome to the Certara Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. To withdraw your question, ...

Second Quarter 2025 Financial Results August 6, 2025 Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the "Company," "Certara," "we," "us," and "our" refer to Certara, Inc. and its consolidated subsidiaries. Trademarks and Service Marks The Certara design logo, "Certara," and our ...

FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39799 Certara, Inc. (Exact name of registrant as specified in its charter) (Stat ...

Exhibit 99.1 Certara Reports Second Quarter 2025 Financial Results Reiterates Full Year 2025 Financial Guidance Second Quarter Highlights: "Our commercial team has continued to field significant interest from customers seeking to expand their use of model- informed drug development," said William F. Feehery, Chief Executive Officer. "We are excited about software product enhancements and new product introductions that will expand our market leading offering and deliver sustainable long- term growth." "We ar ...

RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue was $57.9 million, compare ...

公司动态 - Certara任命Christopher Bouton博士为首席技术官 负责领导下一代集成模型药物开发平台的技术战略与开发 该平台由生成式AI和生物模拟技术驱动 [1] - Bouton博士是Vyasa Analytics创始人兼CEO 该公司2022年被Certara收购 其深度学习软件增强了Certara在多源数据中的预测能力 [2] - Bouton主导开发了多款Certara AI产品 包括用于法规和医学写作的生成式AI工具CoAuthor™ [2] 技术进展 - 新一代建模平台整合科学专业知识 解决方案组合及AI方法 提升新药研发效率和效果 [4] - 生物模拟与生成式AI及机器学习结合 正在重塑新药研发模式 缩短时间线 降低成本并提高成功率 [5] 管理层评价 - CEO评价Bouton为兼具AI专长与药物研发经验的远见领导者 其领导力推动AI生物模拟和虚拟试验的广泛应用 [3] - Bouton表示领导技术战略构建行业最先进AI药物开发平台 将为全球患者带来更好的科学成果 [5] 行业背景 - Certara通过生物模拟软件与服务加速药物研发 客户覆盖70个国家超过2400家生物制药公司 学术机构及监管机构 [5]

公司业绩表现 - Certara公司属于医疗-生物医学和遗传学行业，近期表现出强劲的盈利超预期能力，过去两个季度的平均盈利超出预期11.54% [1] - 最近一个季度公司每股收益为0.14美元，超出Zacks共识预期0.13美元7.69% 前一季度实际每股收益0.15美元，超出预期0.13美元15.38% [2] - 公司目前Zacks Earnings ESP(预期惊喜预测)为+2.44%，结合其Zacks Rank 3(持有)评级，显示分析师近期对公司盈利前景持乐观态度 [8] 盈利预测指标 - Zacks Earnings ESP指标将最准确估计与共识估计进行比较，分析师在财报发布前修正的估计可能包含最新信息，准确性更高 [7] - 研究显示同时具备正Earnings ESP和Zacks Rank 3或更高评级的股票，近70%概率实现盈利超预期 即10只此类股票中可能有7只超预期 [6] - 公司下一份财报预计将于2025年8月6日发布 [8] 指标应用说明 - 负Earnings ESP会降低该指标的预测能力，但负值并不直接预示公司将低于盈利预期 [9] - 许多公司会超出共识EPS预期，但这不是股价上涨的唯一原因 部分股票即使低于预期也可能保持稳定 [10]

药物开发成本 - 药物从临床前研究到商业化的成本估计为10亿美元[1] - 行业需要解决方案来降低这些成本[1] 模型引导药物开发(MIDD) - MIDD是降低药物开发成本的潜在解决方案之一[1] ELAM1公司定位 - 公司为金融专业人士和投资者提供科学和临床专业知识[1] - 帮助客户在医疗保健领域发现隐藏价值并做出更明智的投资决策[1] - 通过弥合尖端科学与金融战略之间的差距来评估风险[1]

文章核心观点 公司将发布2025年第二季度财务结果并召开电话会议讨论 [1] 财务结果发布 - 公司将于2025年8月6日周三收盘后发布2025年第二季度财务结果 [1] - 公司管理层将于美国东部时间下午5点召开电话会议讨论财务结果 [1] 会议参与方式 - 有意收听电话会议的投资者需在线注册，建议提前至少一天注册 [1] - 活动的直播和存档网络直播将在公司网站“投资者”板块提供 [2] 公司简介 - 公司利用生物模拟软件、技术和服务加速药物研发，改变传统药物发现和开发模式 [3] - 公司客户包括70多个国家的超2400家生物制药公司、学术机构和监管机构 [3] 联系方式 - 投资者关系联系人：David Deuchler，Gilmartin Group，邮箱ir@certara.com [4] - 媒体联系人：Alyssa Horowitz，邮箱certara@pancomm.com [4]